Literature DB >> 11833059

Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution.

Gary Meininger1, Colleen Hadigan, Michael Laposata, Joanne Brown, Jessica Rabe, Joseph Louca, Negar Aliabadi, Steven Grinspoon.   

Abstract

Fat redistribution, defined by both increased abdominal visceral fat and/or decreased abdominal, extremity, and facial subcutaneous fat, is increasingly recognized among human immunodeficiency virus (HIV)-infected patients treated with combination antiretroviral therapy. Fat redistribution in this population is associated with insulin resistance and dyslipidemia and is often referred to as the HIV lipodystrophy syndrome (LIPO). Fatty acids are known to modulate insulin resistance in other disease states, but a comprehensive evaluation of fatty acids has not been undertaken among HIV-infected patients with fat redistribution. In this study, we investigated fatty acid concentrations in 64 HIV-infected individuals (45 men and 19 women) with evidence of fat redistribution (LIPO) in comparison to 30 HIV-infected individuals (20 men and 10 women) without evidence of fat redistribution (NONLIPO) and 32 HIV-negative healthy control subjects (C) (21 males and 11 females) of similar age and body mass index (BMI). Glucose, insulin, and free fatty acid (FFA) levels were measured in response to a 75-g oral glucose tolerance test (OGTT) in the LIPO, NONLIPO, and C subjects. In addition, fasting lipids were obtained, and body composition was determined by anthropometric measurements and dual-energy x-ray absorptiometry (DXA). Fasting FFA concentrations were significantly increased in the LIPO group as compared with NONLIPO and C subjects (0.74 +/- 0.03 v 0.60 +/- 0.04 [mean +/- SEM] mmol/L, P =.002, LIPO v NONLIPO; 0.74 +/- 0.03 v 0.59 +/- 0.03 mmol/L, P =.001, LIPO v C). In contrast, fasting FFA concentrations were not increased in the NONLIPO group (0.60 +/- 0.04 v 0.59 +/- 0.03, P =.909, NONLIPO v C). Similarly, fasting triglycerides and 120-minute OGTT FFA were significantly increased in the LIPO group as compared with the NONLIPO and C group. FFA decreased in HIV-infected LIPO, NONLIPO, and C subjects in response to OGTT, but the 120-minute FFA concentrations remained significantly elevated in LIPO patients compared with NONLIPO and C subjects. In a multivariate regression model of LIPO patients, fasting FFA (P =.027) was a strong independent predictor of insulin area under the curve (AUC), controlling for age, BMI, gender, and body composition (r(2) for model =.31). No differences were observed in FFA concentrations in the LIPO group in an analysis based on current protease inhibitor (PI) use. These data suggest that FFA concentrations are increased in HIV-infected patients with fat redistribution. Increased fasting concentrations of fatty acids are associated with abnormal insulin responses to standard glucose challenge in HIV-infected patients with fat redistribution. Further studies are necessary to determine the mechanism of increased fatty acid concentrations and the role played by increased FFA in mediating insulin resistance in this population. Copyright 2002 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11833059     DOI: 10.1053/meta.2002.29999

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  28 in total

Review 1.  Adipose tissue quantification by imaging methods: a proposed classification.

Authors:  Wei Shen; ZiMian Wang; Mark Punyanita; Jianbo Lei; Ahmet Sinav; John G Kral; Celina Imielinska; Robert Ross; Steven B Heymsfield
Journal:  Obes Res       Date:  2003-01

2.  Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia.

Authors:  Colleen Hadigan; James Liebau; Martin Torriani; Rebecca Andersen; Steven Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2006-08-29       Impact factor: 5.958

3.  Endocrinopathies in HIV, AIDS and HAART.

Authors:  Amrit Bhangoo; Ninad Desai
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

Review 4.  Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.

Authors:  Absalon D Gutierrez; Ashok Balasubramanyam
Journal:  Endocrine       Date:  2011-12-02       Impact factor: 3.633

5.  Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis.

Authors:  Diane C Adler-Wailes; Hanguan Liu; Faiyaz Ahmad; Ningping Feng; Constantine Londos; Vincent Manganiello; Jack A Yanovski
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

Review 6.  Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.

Authors:  Erdembileg Anuurad; Alison Semrad; Lars Berglund
Journal:  Metab Syndr Relat Disord       Date:  2009-10       Impact factor: 1.894

Review 7.  Hormonal contraception and HIV-positive women: metabolic concerns and management strategies.

Authors:  Julie Womack; Susan Richman; Phyllis C Tien; Margaret Grey; Ann Williams
Journal:  J Midwifery Womens Health       Date:  2008 Jul-Aug       Impact factor: 2.388

8.  GH/GHRH axis in HIV lipodystrophy.

Authors:  Takara L Stanley; Steven K Grinspoon
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

9.  Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients.

Authors:  B Lindegaard; P Keller; H Bruunsgaard; J Gerstoft; B K Pedersen
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

Review 10.  Metabolic complications associated with HIV protease inhibitor therapy.

Authors:  David Nolan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.